Answers are grounded in this paper and cite their sources.
Gene therapy has become a widely accepted treatment for inherited or acquired genetic diseases. Lentiviral vectors are of particular interest because of their favorable biosafety profile and ability to introduce their therapeutic cargo into non-dividing cells. For clinical use, these viral vectors must be generated under conditions of good manufacturing practice in large quantities, which currently are provided via transient production. A solution for stable, robust, easy to scale, cost-effective, and predictable production of the therapeutic vectors is currently not available. Here, we describe the design, generation, and characterization of EL1-820, a packaging cell line for the stable production of lentiviral self-inactivating (SIN) vectors pseudotyped with the envelope glycoprotein of vesicular stomatitis virus. EL1-820 enables the introduction of a lentiviral SIN-vector expression cassette via Flp-recombinase–mediated cassette exchange (RMCE) into a predefined locus selected for optimal vector production, with expression units designed to improve reliability. EL1-820–based producer clones generated similar titers (1 × 10 7 TU/mL) from a targeted, single-copy integration of a lenti-GFP or a lenti-chimeric antigen receptor transfer vector as transient production. In initial scale-up experiments, multiple harvests from bioreactors could be achieved, resulting in titers of around 8–9 × 10 7 TU/mL after tangential flow filtration and a total yield of about 2.3 × 10 11 TU. In conclusion, RMCE-based introduction of the transfer construct allows stable, defined, predictable, and safe vector production suitable for clinical applications.
No takes yet. Share an insight, caveat, or question.
Heinz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: